Can biochemistry drive drug discovery beyond simple potency measurementsCHENE, Patrick.Drug discovery today. 2012, Vol 17, Num 7-8, pp 388-395, issn 1359-6446, 8 p.Article

Cancer cell senescence: a new frontier in drug developmentCAIRNEY, Claire J; BILSLAND, Alan E; JEFFRY EVANS, T. R et al.Drug discovery today. 2012, Vol 17, Num 5-6, pp 269-276, issn 1359-6446, 8 p.Article

Capillary electrophoresis and small molecule drug discovery: a perfect matchESPADA, Alfonso; MOLINA-MARTIN, Manuel.Drug discovery today. 2012, Vol 17, Num 7-8, pp 396-404, issn 1359-6446, 9 p.Article

Compilation of 222 drugs' plasma protein binding data and guidance for study designsFENGLING ZHANG; JINPIN XUE; JINGWEI SHAO et al.Drug discovery today. 2012, Vol 17, Num 9-10, pp 475-485, issn 1359-6446, 11 p.Article

Curcumin nanoformulations: a future nanomedicine for cancerYALLAPU, Murali M; JAGGI, Meena; CHAUHAN, Subhash C et al.Drug discovery today. 2012, Vol 17, Num 1-2, pp 71-80, issn 1359-6446, 10 p.Article

Determinants for successful marketing authorisation of orphan medicinal products in the EUPUTZEIST, Michelle; HEEMSTRA, Harald E; GARCIA, Jordi Llinares et al.Drug discovery today. 2012, Vol 17, Num 7-8, pp 352-358, issn 1359-6446, 7 p.Article

Foundation review: MRI as a tool for evaluation of oral controlled release dosage formsDOROZYNSKI, Przemysław P; KULINOWSKI, Piotr; MLYNARCZYK, Anna et al.Drug discovery today. 2012, Vol 17, Num 3-4, pp 110-123, issn 1359-6446, 14 p.Article

Foundation review: Progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequateexposureHIGGINS, John; CARTWRIGHT, Mark E; TEMPLETON, Allen C et al.Drug discovery today. 2012, Vol 17, Num 15-16, pp 828-836, issn 1359-6446, 9 p.Article

Foundation review: Reactions and enzymes in the metabolism of drugs and other xenobioticsTESTA, Bernard; PEDRETTI, Alessandro; VISTOLI, Giulio et al.Drug discovery today. 2012, Vol 17, Num 11-12, pp 549-560, issn 1359-6446, 12 p.Article

High-throughput molecular dynamics: the powerful new tool for drug discoveryHARVEY, Matthew J; DE FABRITIIS, Gianni.Drug discovery today. 2012, Vol 17, Num 19-20, pp 1059-1062, issn 1359-6446, 4 p.Article

Hypothesis driven drug design: improving quality and effectiveness of the design- make-test-analyse cyclePLOWRIGHT, Alleyn T; JOHNSTONE, Craig; KIHLBERG, Jan et al.Drug discovery today. 2012, Vol 17, Num 1-2, pp 56-62, issn 1359-6446, 7 p.Article

Improving drug penetration to curb tumor drug resistanceMARCUCCI, Fabrizio; CORTI, Angelo.Drug discovery today. 2012, Vol 17, Num 19-20, pp 1139-1146, issn 1359-6446, 8 p.Article

Metrics and the effective computational scientist: process, quality and communicationBALDWIN, Eric T.Drug discovery today. 2012, Vol 17, Num 17-18, pp 935-941, issn 1359-6446, 7 p.Article

New pharmacological approaches to atrial fibrillationMILNES, James T; MADGE, David J; FORD, John W et al.Drug discovery today. 2012, Vol 17, Num 13-14, pp 654-659, issn 1359-6446, 6 p.Article

Nucleic acid sample preparation for in vitro molecular diagnosis: from conventional techniques to biotechnologyMAHBUBOR RAHMAN, Md; ELAISSARI, Abdelhamid.Drug discovery today. 2012, Vol 17, Num 21-22, pp 1199-1207, issn 1359-6446, 9 p.Article

Orphan drug development: an economically viable strategy for biopharma R&DMEEKINGS, Kiran N; WILLIAMS, Cory S. M; ARROWSMITH, John E et al.Drug discovery today. 2012, Vol 17, Num 13-14, pp 660-664, issn 1359-6446, 5 p.Article

Relevance of systems pharmacology in drug discoveryCUCURULL-SANCHEZ, Lourdes; SPINK, Karen G; ATHANASIOS MOSCHOS, Sterghios et al.Drug discovery today. 2012, Vol 17, Num 13-14, pp 665-670, issn 1359-6446, 6 p.Article

Should medicinal chemists do molecular modelling?RITCHIE, Timothy J; MCLAY, Lain M.Drug discovery today. 2012, Vol 17, Num 11-12, pp 534-537, issn 1359-6446, 4 p.Article

Strategic alliances and market riskHAVENAAR, Matthias.Drug discovery today. 2012, Vol 17, Num 15-16, pp 824-827, issn 1359-6446, 4 p.Article

Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problemHAO, Ge-Fei; YANG, Guang-Fu; ZHAN, Chang-Guo et al.Drug discovery today. 2012, Vol 17, Num 19-20, pp 1121-1126, issn 1359-6446, 6 p.Article

Therapeutic stratagems for vascular degenerative disorders of the posterior eyeJAIN, Gaurav K; WARSI, Musarrat H; NIRMAL, Jayabalan et al.Drug discovery today. 2012, Vol 17, Num 13-14, pp 748-759, issn 1359-6446, 12 p.Article

What is the most important approach in current drug discovery: doing the right things or doing things right?ELEBRING, Thomas; GILL, Adrian; PLOWRIGHT, Alleyn T et al.Drug discovery today. 2012, Vol 17, Num 21-22, pp 1166-1169, issn 1359-6446, 4 p.Article

New therapeutic approaches to treating hypertension in pregnancyMATE, Alfonso; VAZQUEZ, Carmen M; LEIVA, Andrea et al.Drug discovery today. 2012, Vol 17, Num 23-24, pp 1307-1315, issn 1359-6446, 9 p.Article

Aurora-A kinase inhibitor scaffolds and binding modesAIXIA YAN; LIYU WANG; SHUYU XU et al.Drug discovery today. 2011, Vol 16, Num 5-6, pp 260-269, issn 1359-6446, 10 p.Article

Chromatin modifying agents - the cutting edge of anticancer therapyKWA, Faith A. A; BALCERCZYK, Aneta; LICCIARDI, Paul et al.Drug discovery today. 2011, Vol 16, Num 13-14, pp 543-547, issn 1359-6446, 5 p.Article